FDC vs MANKIND: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. FDC shows a lower P/E, a higher dividend yield and faster revenue growth, while MANKIND PHARMA shows a higher ROE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
FDC leads 8; MANKIND leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | FDC | MANKIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | FDC | MANKIND |
|---|---|---|
| Live Price | ₹379 | ₹2,508.8 |
| Day Change | 0.49% | 1.6% |
| Volume | 1.09 L | 1.61 L |
| 52-Week High | ₹473.6 | ₹2,642 |
| 52-Week Low | ₹312.95 | ₹1,909.7 |
| Distance from 52W High | -19.97% | -5.04% |
Valuation
| Metric | FDC | MANKIND |
|---|---|---|
| Market Cap | ₹6,205 Cr | ₹1.03 L Cr |
| P/E Ratio | 19.53x | 45.19x |
| P/B Ratio | 2.3x | 5.78x |
| EPS | ₹19.24 | ₹13.9 |
| Book Value | ₹163.75 | ₹401 |
| Dividend Yield | 2.66% | 0% |
Growth
| Metric | FDC | MANKIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 18.9% | 11.8% |
| EPS Growth (TTM YoY) | 166.8% | 31.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | FDC | MANKIND |
|---|---|---|
| ROE | 11.47% | 11.7% |
| ROCE | 11.69% | 10.93% |
| Net Margin | 12.96% | 13.34% |
| Operating Margin | 18.03% | 20.73% |
| Debt to Equity | 0x | 0.38x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | FDC | MANKIND |
|---|---|---|
| Promoter Holding | 69.66% | 72.62%▼ 0.01 pp |
| FII Holding | 1.58%▲ 0.18 pp | 9.37%▼ 0.08 pp |
| DII Holding | 6.59%▲ 0.28 pp | 15.56%▲ 0.17 pp |
| Public Holding | 22.17%▼ 0.46 pp | 2.45%▼ 0.08 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FDC and MANKIND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.